Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROH-SET Study
2024-516753-45-00Phase 2Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Mar 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of setmelanotide in Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD), sponsored by University Medical Center Utrecht. Planned start Mar 2025; status: authorised.
02
Drugs
setmelanotide
03
Conditions
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD)
Beyond the preview
Go deeper on 2024-516753-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516753-45-00.